Report

Monthly New Drug and First Time Generic July 2023



New Brand Drug Pipeline

Medication (Trade Name)	Drug Class		Therapeutic Use	Status Update
Nalmefene Nasal Spray (Opvee®)	Opioid Antagonist		Opioid Overdose	Launch pending. Approved May 2023.
Buprenorphine Depot Injection (Brixadi™)	Opioid Antagonist		Treatment of Opioid Addiction	Launch pending. Approved May 2023.
Ansofaxine	Antidepressant		Major Depressive Disorder	FDA review pending.
Oxycodone (Aximris XR™)	Opioid Analgesic - Extended Release		Pain	FDA review pending.
Meloxicam/Rizatriptan	NSAID/Serotonin Agonist		Migraine Headache	FDA review pending.
Naloxone Nasal Spray (RiVive™)	Opioid Antagonist		Opioid Overdose	FDA review pending for OTC formulation
Gepirone ER (Exxua™)	Antidepressant		Major Depressive Disorder	FDA review pending.
Zuranolone	Antidepressant		Major Depressive Disorder	FDA review pending.
Generic Pipeline				
Medication (Trade Name)	Drug Class Therap		eutic Use	Status Update
Гiotropium (Spiriva® H andihaler®)	Bronchodilator Chronic Disease		Obstructive Pulmonary	Generic approved June 2023
Cariprazine (Vraylar®)	Antipsychotic Schizophrenia & Bipolar I Disord		hrenia & Bipolar I Disordo	er Generic approved September 2022.
Apixaban (Eliquis®)			ent/Prophylaxis Vein Thrombosis	Generics approved December 23, 201 but settlements expected to del
Available in the last 1	2 months			launch for at least a few years.
Medication (Trade Name)	Drug Class		Therapeutic Use	Status Update
Bupropion/Dextromethorphan (Auvelity™)	Antidepressant		Major Depressive Disorder	October 2022
Newly Available Generics				
Baclofen Oral Suspension	Skeletal Muscle Relaxant		Spasticity	June 2023
(Fleqsuvy®) Lurasidone (Latuda®)	Antidepressant		Depression	February 2023
Diclofenac Potassium (Cambia ®) Solution	NSAID		Migraine Headache Treatment	January 2023
Topiramate (Trokendi XR®)	Anticonvulsant		Neuropathic Pain	January 2023

Report

Monthly New Drug and First Time Generic July 2023



Discontinuations & Withdrawals

Medication (Trade Name) Drug Class Therapeutic Use Status Update

Beclomethasone Nasal (Beconase AQ®)

Nasal Steroid Allergies

Anticipated date of ceased distribution is approximately November 2023.